Filtered By:
Countries: Finland Health

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 173 results found since Jan 2013.

Family aggregation of cardiovascular disease mortality: a register-based prospective study of pooled Nordic twin cohorts
ConclusionsFamily aggregation was found for CHD and haemorrhagic stroke. Clustering of risk factors in families increases the risk of CVD.
Source: International Journal of Epidemiology - February 28, 2017 Category: Epidemiology Source Type: research

Regional trends in avoidable hospitalisations due to complications among population with diabetes in Finland in 1996-2011: a register-based cohort study
Conclusions Our study suggests that the prevention of complications among persons with diabetes has improved in Finland between 1996 and 2011. The results further suggest that the prevention of complications has become more uniform throughout the country.
Source: BMJ Open - August 21, 2016 Category: Journals (General) Authors: Manderbacka, K., Arffman, M., Lumme, S., Lehikoinen, M., Winell, K., Keskimäki, I. Tags: Open access, Health services research, Diabetes and Endocrinology Source Type: research

Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
Purpose The aim of the Medicine use and Alzheimer's disease (MEDALZ) study is to investigate the changes in medication and healthcare service use among persons with Alzheimer's disease (AD) and to evaluate the safety and effectiveness of medications in this group. This is important, because the number of persons with AD is rapidly growing and even though they are a particularly vulnerable patient group, the number of representative, large-scale studies with adequate follow-up time is limited. Participants MEDALZ contains all residents of Finland who received a clinically verified diagnosis of AD between 2005 and 2011 and ...
Source: BMJ Open - July 12, 2016 Category: Journals (General) Authors: Tolppanen, A.-M., Taipale, H., Koponen, M., Lavikainen, P., Tanskanen, A., Tiihonen, J., Hartikainen, S. Tags: Open access, Epidemiology, Neurology, Pharmacology and therapeutics Cohort profile Source Type: research

De Novo Aneurysm Formation in Carriers of Saccular Intracranial Aneurysm Disease in Eastern Finland Clinical Sciences
Conclusions— Patients aged < 40 years at the first sIA diagnosis are in a significant risk of developing de novo sIAs, and they should be scheduled for long-term angiographic follow-up. Smoking increases the risk of de novo sIA formation, suggesting long-term follow-up for smokers. Antismoking efforts are highly recommended for sIA patients.
Source: Stroke - April 24, 2016 Category: Neurology Authors: Lindgren, A. E., Raisanen, S., Bjorkman, J., Tattari, H., Huttunen, J., Huttunen, T., Kurki, M. I., Frosen, J., Koivisto, T., Jaaskelainen, J. E., von und zu Fraunberg, M. Tags: Clinical Studies, Epidemiology, Risk Factors, Cerebral Aneurysm, Intracranial Hemorrhage Clinical Sciences Source Type: research

Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy: A Finnish retrospective study
Conclusion First-generation AEDs are still the most commonly employed first drugs for elderly patients with newly diagnosed epilepsy in Finland. Age and comorbid conditions have an effect in the choice of the initial AED treatment.
Source: Seizure - July 5, 2015 Category: Neurology Source Type: research

Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation, p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.
Source: Journal of Thrombosis and Haemostasis - October 10, 2013 Category: Hematology Authors: M. Puurunen, P. Salo, S. Engelbarth, K. Javela, M. Perola Tags: Original Article Source Type: research

Type II Antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population - clinical picture.
CONCLUSION: In Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening. This article is protected by copyright. All rights reserved. PMID: 23910795 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 3, 2013 Category: Hematology Authors: Puurunen M, Salo P, Engelbarth S, Javela K, Perola M Tags: J Thromb Haemost Source Type: research

Type II Antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population – clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - July 1, 2013 Category: Hematology Authors: M Puurunen, P Salo, S Engelbarth, K Javela, M Perola Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research